Lymph-Node Targeted TLR9 Agonists Enable Potent Cellular Immune Responses Against Cancer & Infectious Disease

Time: 4:00 pm
day: Day One


  • Dissecting what exactly is lacking in the current models and bridging the translation gap
  • Exploring how we can design/strategize/use the right models to really represent what we want
  • Exploring what constitutes sensitivity
  • Using models to predict the severe side effects seen in humans
  • Understanding what the best setting is to do efficacy/new target discovery for optimizing compounds and biomarker discovery
  • Toxicity models – what preclinical models are out there that could help us to identify toxicity of these therapies?